

# WOAH Reference Laboratory Reports Activities 2022

## Activities in 2022

This report has been submitted : 25 avril 2023 16:11

### Laboratory Information

<b>Name of disease (or topic) for which you are a designated WOAHO Reference Laboratory:</b>	Infection with koi herpesvirus
<b>Address of laboratory:</b>	422-1 Nakatsuhamaura Minami-Ise, Mie, 516-0193
<b>Tel.:</b>	+81599661830
<b>E-mail address:</b>	ito_takafumi99@fra.go.jp
<b>Website:</b>	<a href="https://www.fra.affrc.go.jp/english/eindex.html">https://www.fra.affrc.go.jp/english/eindex.html</a>
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Takashi Kamaishi (PhD), Director of Pathology Division
<b>Name (including Title and Position) of WOAHO Reference Expert:</b>	Takafumi Ito (PhD), Deputy Director of Pathology Division
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental Research agency

### TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAHO Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
ELISA	No	0	0
Direct diagnostic tests		Nationally	Internationally
PCR with Sph primer	Yes	15	

			0
PCR with TK primer	Yes	15	0

## **TOR2: REFERENCE MATERIAL**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAHP?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAHP Members?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHP Members?

No

## **TOR3: NEW PROCEDURES**

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHP Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAHP Standards for the designated pathogen or disease?

No

## **TOR4: DIAGNOSTIC TESTING FACILITIES**

10. Did your laboratory carry out diagnostic testing for other WOAHP Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHP Member?

Yes

NAME OF THE WOAHP MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
MALAYSIA	Regarding detecting koi herpesvirus in latent infection	remote

## **TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES**

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

No

## **TOR6: EPIZOOLOGICAL DATA**

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

We collected epidemiological data for a novel cyprinid herpesvirus, which is called as 'KHV variant' by an OIE export of the disease.

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1

Yuasa K, Kawana M, Ito T, Kiryu I, Oseko N, Sano M. Intra vitam assays for detecting fish infected with cyprinid herpesvirus 3 (CyHV-3), *Dis Aquat Org*, 149, 77-82, 2022

b) International conferences:

3

Kurobe T, Takada T, Nitta M, Inada M, Kawato Y, Kiryu I, Miwa S, Ito T, Dealing with unknowns- investigation on novel and emerging pathogens in Japan. 50th Scientific Symposium of the US-Japan Natural Resources Aquaculture Panel, November 2022.  
Kawato Y, Takada Y, Kurobe T, Nakagawa Y, Ito T. Monitoring red sea bream iridovirus in aquaculture environment using environmental DNA to understand disease outbreaks, 50th Scientific Symposium of the US-Japan Natural Resources Aquaculture Panel, November, 2022.  
Takano T, Matsuyama T, Sakai T, Miwa S, Kiryu I, Honjyo M, Nawata A, Matsuura Y, Yamasaki M, Terashima S, Kurita J, Ito T, Kumagai A, Nakayasu C. Studies on erythrocytic inclusion body syndrome (EIBS) in farmed coho salmon based on genome sequence of the causative agent piscine orthoreovirus 2 (PRV-2), 50th Scientific Symposium of the US-Japan Natural Resources Aquaculture Panel, November, 2022.

c) National conferences:

1

Kurobe T, Yuasa K, Mekata T, Ito T, Development of diagnostic PCR assay for low virulent KHV strain. National Conference of Fish Pathology, September 2022.

d) Other (Provide website address or link to appropriate information):

## TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Members?

No

## TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO17025	ISO certificate of accreditation	ISO certificate of accreditation.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
PCR	Perry Johnson Laboratory Accreditation, Inc.

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

Access to the laboratory is restricted. Personnel uses PPEs and follows basic laboratory procedures to avoid accidental exposure to the pathogen. All contaminated lab supplies (e.g., dissecting tools) are autoclaved to prevent the pathogen from releasing into the environment.

## TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHP?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHP?

No

## TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

No

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOAHP REF. LABS/ ORGANISING WOAHP REF. LAB.
Determining a laboratory's capability to conduct specific diagnostic tests (EU ring test)	Participant	46	National Institute for Aquatic Resources , Technical University of Denmark

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the

diagnosis or control of the pathogen of interest?

No

## TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons <sup>1</sup>	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Region(s) of participating WOAHP Member Countries
Determining a laboratory's capability to conduct specific diagnostic tests (National ring test)	Organizer	13	Asia and Pacific

## TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

Yes

KIND OF CONSULTANCY	Location	SUBJECT (FACULTATIVE)
Rewriting and providing comments on OIE Manual of KHV disease (Chapter 2.3.7)	Japan	Rewriting OIE manual of KHV disease

29. Additional comments regarding your report:

Yes